AtCor Medical

AtCor Medical today announced a second positive case ruling by an Administrative Law Judge for the Centers for Medicare and Medicaid Services. Specifically, the judge disagreed with the findings of a Medicare health plan assessment in the state of Michigan that the SphygmoCor technology is experimental and ruled that the plan must provide coverage for use of the SphygmoCor System.

Please click here to view the ASX/media release

Please click here to view the ruling

For reimbursement support in the USA, please contact Renee Koziol, RN on:
+1 (630) 228 8871 or r.koziol@atcormedical.com

For reimbursement support in Australia, please contact Mark Harding on:
+61 (2) 9874 8761 or m.harding@atcormedical.com

US$1.77 Million New Pharmaceutical Contract - US$2.9m New Contracts in Past Three Months

7 July 2010

AtCor Medical today announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The US$1.77m contract is with an existing AtCor customer.

Please click here to view the ASX/media release

Positive Medicare Coverage Ruling in Michigan - Requires Medicare Plan to Cover SphygmoCor System

26 May 2010

AtCor Medical today announced a positive case ruling by an Administrative Law Judge for the Centers for Medicare and Medicaid. Specifically, the judge found that a Medicare health plan in the state of Michigan must provide coverage for use of the SphygmoCor System.

Please click here to view the ASX/media release

Please click here to view the ruling

For reimbursement support in the USA, please contact Renee Koziol, RN on:
+1 (630) 228 8871 or r.koziol@atcormedical.com

For reimbursement support in Australia, please contact Mark Harding on:
+61 (2) 9874 8761 or m.harding@atcormedical.com

Mayo Clinic Publication Supports Central Blood Pressure Measurement

11 May 2010

AtCor Medical today announced that the peer-reviewed medical journal, Mayo Clinic Proceedings, has published a major review of scientific literature on noninvasive central blood pressure measurement in its May 2010 issue.

Please click here to view the ASX/media release

New Pharmaceutical Contract

21 April 2010

AtCor Medical today announced that it has signed a new US$265,000 contract with a major international pharmaceutical company. This is an extension to an existing contract to supply SphygmoCor systems and clinical trials support services. A large portion of the contract value will be recognised in the current financial year.

Please click here to view the ASX/media release

Business Update

19 April 2010

AtCor Medical today released its business update for 2010.

Please click here to view the ASX/media release

Third Quarter Report - Appendix 4C

15 April 2010

AtCor Medical today released its quarterly cash flow report for the period ending 31 March 2010.

Please click here to view the ASX/media release

US$0.95 Million New Pharmaceutical Contract

30 March 2010

AtCor Medical today announced that it has signed a new agreement with a major international pharmaceutical company to supply SphygmoCor systems and clinical trials support services. The US$955,000 contract is a new agreement with an existing AtCor customer. A large portion of the contract value will be recognised in the current financial year. AtCor has an ongoing pipeline of new business opportunities and anticipates additional pharmaceutical contracts in the current financial year.

Please click here to view the ASX/media release

Another Study Using AtCor’s SphygmoCor System Demonstrates Importance of Central Blood Pressure Measurement - Non-Invasive Central Blood Pressure Assessment Reveals Important Drug Effect Not Detectable by Conventional Methods

19 March 2010

AtCor Medical today announced that its SphygmoCor® system has played a key role in a new study that points to new and potentially better treatment options for hypertension. The study, conducted by researchers from Emory University, Baylor College of Medicine, the University of Pennsylvania and Novartis Corporation (NYSE:NVS) was presented on March 16th, at the 2010 American College of Cardiology Scientific Sessions.

Please click here to view the ASX/media release

AtCor Medical Launches New Platform for Clinicians

16 March 2010

AtCor Medical this week launched its latest SphygmoCor software (Version 9) at the Annual American College of Cardiology Scientific Session Exposition being held in Atlanta on March 14-16, 2010.

Please click here to view the ASX/media release

AtCor Releases Half Year Results

19 February 2010

AtCor Medical today released its H1 FY2010 results.

Please click here to view the ASX/media release

SphygmoCor Uncovers Positive Drug Effects in Pre-Eclampsia Patients

17 February 2010

AtCor Medical today announced that a University of Illinois Medical Center, Chicago study1 has highlighted an important new inpatient use for SphygmoCor: monitoring the effects of drug therapy in hospitalised patients with pre-eclampsia, a potentially life-threatening complication of pregnancy.

Please click here to view the ASX/media release

Central BP a Superior Determinant of Left Ventricular Hypertrophy -- New Study Highlights Importance of Central Pressure in Patient Care and Clinical Trials

02 February 2010

AtCor Medical today announced a new National Institutes of Health (NIH)-funded study, published in the Journal of Hypertension, has found that central (aortic) blood pressure, measured noninvasively, is a more important indicator of the development of left ventricular hypertrophy (LVH) than is brachial blood pressure. LVH relates to muscle thickening in the heart’s pumping chamber. Its incidence increases with age and is more common in people who have high blood pressure.

Please click here to view the ASX/media release

1st Half Market Update

28 January 2010

AtCor Medical today announced unaudited H1 FY2010 sales of $4.4 million, a 13% decline in constant currency terms from the record H1 sales in FY2009. This figure does not include a large pharma order that had been expected in December and is now expected to close within the next 30 days. Without this delay the business would have reported positive growth for the half in constant currency. Non-pharma sales for the half grew 17% pcp in constant currency.

Please click here to view the ASX/media release

Second Quarter Report - Appendix 4C

28 January 2010

AtCor Medical today released its quarterly cash flow report for the period ending 30 December 2009.

Please click here to view the ASX/media release